Centrus Energy Corp. (LEU) Stock Analysis

40.0/100
Sell Not Halal Energy
Price $103.78
Market Cap $2.07B
52-Week Change -59.12%

Is LEU a good investment?

Centrus Energy Corp. (LEU) has a Plutrex AI rating of 40.0/100 as of November 12, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: HALEU Monopoly with $4.5B contracted backlog: Centrus remains the SOLE U.S. producer of High-Assay Low-Enriched Uranium — the fuel for next-generation reactors. Headlines confirm centrifuge shipments to Ohio and ahead-of-schedule capacity expansion milestones, validating operational execution. This irreplaceable bottleneck asset in the advanced nuclear fuel supply chain provides strategic optionality that no DCF model fully captures, particularly as U.S. restrictions on Russian uranium imports create structural demand tailwinds.. Main concern: Systematic analyst target erosion confirms secular decline: The consensus target has been cut FOUR consecutive times: $223.78 → $212.75 → $174.20 → $167.80. This -$6.40 current cut (-3.7%) continues the trend, reducing the implied upside from 55.6% (prior report) to 49.6% (current), but more importantly signals ongoing downward revision risk. Combined with revenue growth collapsing from +14% to -25.9% YoY and FCF deteriorating from -$163.8M to -$295.5M, the operational trajectory is worsening, not stabilizing. The P/E drop from 50.38x to 33.4x is a negative signal (earnings quality erosion) dressed up as a positive..

Investment Summary

Centrus Energy (LEU) at $112.17 remains a structurally challenged speculative play with one irreplaceable strategic asset — its HALEU monopoly — but deteriorating fundamentals make the risk/reward unattractive at current prices. P/E has compressed from 50.38x to 33.4x (a positive), but this improvement is driven by earnings base distortion, not operational recovery. Revenue contracted -25.9% YoY and EPS collapsed -76.4% YoY. Five-year EPS CAGR projects -6.8% annually — cumulative ~30% earnings erosion. The analyst consensus target was cut AGAIN from $174.20 to $167.80 (-$6.40, -3.7%), continuing the systematic downward revision trend (from $223.78 → $212.75 → $174.20 → $167.80 over three reports). Operating margin of -2.77% confirms core operations are unprofitable; net margin of 16.77% is entirely non-operational. The company burns -$295.5M FCF annually against $2.24B cash (~7-8 year runway). The HALEU monopoly with $4.5B contracted backlog and centrifuge expansion progress provides real optionality value that prevents a 'Sell' rating, but the entry math only works at materially lower prices than $112.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
35/100
Growth Potential
15/100
Valuation
30/100
Profitability
52/100
Debt Management
28/100
Analyst Sentiment
42/100
Technical Momentum
35/100
Insider Confidence
42/100
News Sentiment
60/100

Fundamental Analysis

LEU's fundamentals have deteriorated materially since the prior report on three key vectors: (1) VALUATION: P/E compressed from 50.38x to 33.4x, which appears positive but reflects the EPS denominator being inflated by non-operating items (warrant gains per Q3 call), not genuine earnings improvement. The 33.4x P/E for a company with -6.8% 5-year EPS CAGR implies ~65-77% overvaluation vs. fair value of $26-40 on a DCF basis. PEG remains N/A — the highest red flag in growth-adjusted valuation. (2) GROWTH: Revenue growth collapsed from +14.0% (prior report) to -25.9% (current) — a 285% swing that represents catastrophic top-line deterioration. EPS growth YoY is -76.4%. Five-year EPS CAGR is -6.8% vs. industry +23.3% — a 3,007 bps deficit. The industry is in a generational nuclear renaissance; LEU is not participating. (3) HEALTH: D/E improved slightly from 1.39x to 1.07x (possibly debt reduction using cash), but remains 267% above the industry average of 0.29x. FCF worsened from -$163.8M to -$295.5M (an $131.7M deterioration, -80% YoY) — the opposite direction from prior report's improvement trend. Cash of $2.24B provides 7-8 year runway vs. 11.4 year estimate in prior report, confirming accelerating cash burn. ROE of 10.38% remains positive vs. industry -0.72%, and gross margin 21.52% edges industry 20.39%, but these are the only genuine positives.

News Sentiment

Centrus Energy is navigating a defining crossroads between strategic promise and operational reality, and Wall Street is watching closely. The stock grabbed attention this week when an analyst made a notable bullish turn, appearing in the 'Top 5 Upgrades For Friday' — a rare positive signal for a company whose shares crashed 26% in October, as detailed in the headline 'Why Centrus Energy Stock Crashed 26% in October.' That sell-off reflected investor frustration with slowing commercial revenue, but the upgrade suggests at least one influential voice sees a turnaround brewing. The Q3 earnings report told a complicated story. Per 'LEU Q3 Earnings Beat Estimates on Warrant Gain, Sales Decline,' the company technically exceeded Wall Street estimates — but the beat was driven by a one-time warrant gain, not core business growth. Sales actually declined, confirming that Centrus' commercial uranium enrichment segment is under real pressure. The brighter news came from the company's operational progress. The 'Centrus Energy Q3 Earnings Call Highlights Enrichment Expansion Progress' headline and companion Q3 call summary revealed ahead-of-schedule centrifuge manufacturing milestones and construction certification advances — meaningful steps toward commercializing HALEU, the advanced nuclear fuel that Centrus uniquely produces in the U.S. For everyday investors, the picture is this: Centrus owns a potentially invaluable strategic asset in a world moving toward nuclear energy, but the financial results right now don't yet match that promise. The stock needs to prove its HALEU expansion translates into real revenue growth — and at $112, the market may be pricing in that proof prematurely.

Risk Assessment

PRIMARY RISK: Continued analyst target erosion — from $223.78 to $167.80 over three reports, the target trajectory suggests further cuts are more likely than upgrades given the -25.9% revenue contraction and -6.8% 5-year EPS CAGR. If the target resets to $130-$140, the investment thesis collapses entirely at current prices. SECONDARY RISK: FCF burn acceleration — the deterioration from -$163.8M to -$295.5M (-80%) in one period suggests potential for the 7-8 year cash runway to compress further, raising dilution or debt refinancing risk given D/E of 1.07x vs. industry 0.29x. TERTIARY RISK: HALEU commercialization delay — the entire bull case rests on HALEU demand materializing before cash runs out; any regulatory or demand setback could collapse the strategic optionality premium. MITIGATION: Small position size (0.75%), stop-loss at $78 (structural support, ~16% below entry), and long time horizon to allow HALEU optionality to develop. The HALEU monopoly prevents a 'Sell' — but the math requires entry below $98.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is LEU a halal stock?

No, Centrus Energy Corp. (LEU) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for LEU?

Centrus Energy Corp. (LEU) has a Plutrex AI rating of 40.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is LEU a good investment?

According to Plutrex AI, LEU has a Sell rating (40.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in LEU?

US stocks like LEU can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in LEU?

Plutrex AI identifies the main risks for LEU by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about LEU

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open LEU in ElBarake